Retinal Vein Occlusion Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Kodiak Sciences, Hoffman-La-Roche, Irenix Medical, Inc., Sunshine Guojian Pharmace

(MENAFN- GetNews)


"Retinal Vein Occlusion Pipeline"DelveInsight's,“Retinal Vein Occlusion - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 15 key companies are actively engaged in developing more than 15 therapies for the treatment of Retinal Vein Occlusion.

Retinal Vein Occlusion Overview:

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder and a leading cause of vision loss in older adults. It is classified into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). CRVO occurs when the main retinal vein becomes obstructed behind the lamina cribrosa of the optic nerve, most often due to thrombosis. It is further divided into non-ischemic (perfused) and ischemic (non-perfused) types, with the non-ischemic form accounting for about 70% of cases.

Age is the strongest risk factor for CRVO, with 90% of cases occurring in people over 50. Other major risks include systemic hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia. Additional factors include smoking, optic disc drusen or edema, and various hypercoagulable states such as polycythemia, multiple myeloma, cryoglobulinemia, Waldenström macroglobulinemia, antiphospholipid syndrome, factor V Leiden mutation, activated protein C resistance, hyperhomocysteinemia, and deficiencies in Protein C, Protein S, or antithrombin III. Conditions such as syphilis, sarcoidosis, sickle cell disease, HIV, vasculitis, and certain medications like oral contraceptives or diuretics may also contribute. In rare cases, migraines or orbital diseases can play a role in the onset of CRVO.

Request for a detailed insights report on Retinal Vein Occlusion pipeline insights

"Retinal Vein Occlusion Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Retinal Vein Occlusion Therapeutics Market.

Key Takeaways from the Retinal Vein Occlusion Pipeline Report

• DelveInsight's Retinal Vein Occlusion (RVO) pipeline report showcases an active landscape with more than 15 companies working on over 15 potential therapies.

• Key players include Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others, all striving to improve RVO treatment options.

• Prominent candidates in development include KSI-301, 601, and IBE-814, among others.

• In December 2025, Regeneron and Bayer announced that Eylea HD (aflibercept 8 mg) achieved its primary endpoint in a Phase III trial for macular edema following RVO. Patients treated every eight weeks with Eylea HD achieved non-inferior visual gains compared to the original Eylea administered every four weeks, indicating the potential for extended dosing intervals and reduced treatment burden. Regeneron intends to submit these findings to the FDA in early 2025 to expand Eylea HD's indications to include RVO.

• In October 2023, the U.S. FDA approved Genentech's Vabysmo (faricimab-svoa) for macular edema following RVO, based on positive Phase III BALATON and COMINO trial results. Monthly Vabysmo injections delivered early and sustained vision improvements in both branch and central RVO, achieving non-inferior visual acuity gains at 24 weeks compared to aflibercept, along with rapid and significant retinal fluid reduction. The safety profile aligned with prior studies, with conjunctival hemorrhage (3%) as the most common adverse event.

Retinal Vein Occlusion Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Retinal Vein Occlusion Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Retinal Vein Occlusion market.

Download our free sample page report on Retinal Vein Occlusion pipeline insights

Retinal Vein Occlusion Emerging Drugs

• KSI-301: Kodiak sciences

• 601: Sunshine Guojian Pharmaceutical

• IBE-814: Ripple Therapeutics

Retinal Vein Occlusion Companies

Over 15 leading companies are actively engaged in developing treatments for Retinal Vein Occlusion, with Kodiak Sciences advancing a drug candidate currently in Phase III clinical trials.

DelveInsight's report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Retinal Vein Occlusion Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Retinal Vein Occlusion Therapies and Key Companies: Retinal Vein Occlusion Clinical Trials and advancements

Retinal Vein Occlusion Pipeline Therapeutic Assessment

. Retinal Vein Occlusion Assessment by Product Type

. Retinal Vein Occlusion By Stage

. Retinal Vein Occlusion Assessment by Route of Administration

. Retinal Vein Occlusion Assessment by Molecule Type

Download Retinal Vein Occlusion Sample report to know in detail about the Retinal Vein Occlusion treatment market @ Retinal Vein Occlusion Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Retinal Vein Occlusion Current Treatment Patterns

4. Retinal Vein Occlusion - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Retinal Vein Occlusion Late-Stage Products (Phase-III)

7. Retinal Vein Occlusion Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinal Vein Occlusion Discontinued Products

13. Retinal Vein Occlusion Product Profiles

14. Retinal Vein Occlusion Key Companies

15. Retinal Vein Occlusion Key Products

16. Dormant and Discontinued Products

17. Retinal Vein Occlusion Unmet Needs

18. Retinal Vein Occlusion Future Perspectives

19. Retinal Vein Occlusion Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Retinal Vein Occlusion Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN11082025003238003268ID1109914614